Antidiabetic and antihyperlipidemic potential of ethanol extract of Salacia lehmbachii stem bark in alloxan-induced diabetic rats

Background Salacial lehmbachii stem bark is used traditionally for the treatment of diabetes mellitus and its associated complications. Treatment of diabetes is necessary to reduce these complications. Methods In this study, the antidiabetic and antihyperlipidemic potential of S. lehmbachii ethanol...

Full description

Saved in:
Bibliographic Details
Published inJournal of basic and clinical physiology and pharmacology Vol. 30; no. 2; p. 239
Main Authors Akuodor, Godwin C, Eban, Linus K, Ajoku, Gloria Ahunna, Nwobodo, Ndubuisi N, Akpan, Joseph L, Ezeokpo, Basil C, Nwadike, Kenneth I, Aja, Daniel Oj
Format Journal Article
LanguageEnglish
Published Germany 23.10.2018
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Background Salacial lehmbachii stem bark is used traditionally for the treatment of diabetes mellitus and its associated complications. Treatment of diabetes is necessary to reduce these complications. Methods In this study, the antidiabetic and antihyperlipidemic potential of S. lehmbachii ethanol stem bark extract was evaluated in alloxan-induced diabetic rats at a dose of 100 mg/kg, 200 mg/kg, and 400 mg/kg p.o. daily for 21 days. Blood glucose levels, serum total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL) were assessed in the animals. Results Treatment of alloxan-induced diabetic rats with S. lehmbachii stem bark extract showed significant (p<0.01) reduction in blood glucose levels when compared with diabetic control. The elevated levels of serum cholesterol, triglycerides, LDL, and VLDL were significantly (p<0.01) reduced by S. lehmbachii stem bark extract, while the level of HDL significantly (p<0.01) increased. Conclusions The results obtained suggest that S. lehmbachii stem bark extract has the potential to treat diabetes condition and hyperlipidemic disorders.
ISSN:2191-0286